Abstract

The emergent healthcare value era, its consequences, and what drug firms need to do about it

1. Michael J. Russo and David Balekdjian are partners at The Bruckner Group, 27 Water Street, Suite 409, Wakefield, MA 01880 (http://www.brucknergroup.com), a strategy consulting company. The Bruckner Group is an industry leader in healthcare value strategy, assisting pharma and biotech executives in developing business models, enterprise-wide processes and individual drug strategies that result in products with high healthcare value, meeting the needs of patients, physicians and payers. e-mail: dbalekdjian@brucknergroup.com

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

NPG Journals

by Subject Area

• Chemistry

  • Chemistry
  • Drug discovery
  • Biotechnology
  • Materials
  • Methods & Protocols

• Clinical Practice & Research

  • Cancer
  • Cardiovascular medicine
  • Dentistry
  • Endocrinology
  • Gastroenterology & Hepatology
  • Methods & Protocols
  • Pathology & Pathobiology
  • Urology

• Earth & Environment

  • Earth sciences
  • Evolution & Ecology

• Life sciences

  • Biotechnology
  • Cancer
  • Development
  • Drug discovery
  • Evolution & Ecology
  • Genetics
  • Immunology
  • Medical research
  • Methods & Protocols
  • Microbiology
  • Molecular cell biology
  • Neuroscience
  • Pharmacology
  • Systems biology

• Physical sciences

  • Physics
  • Materials

by A - Z Index